Hematologic Oncology Update Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Nov 13, 2025
Dr. Matthew Lunning, an expert in B-cell lymphomas, discusses CAR T-cell therapy's logistics and its efficacy against standard care in high-risk diffuse large B-cell lymphoma (DLBCL). Alongside him, Dr. Sonali M. Smith, a senior lymphoma investigator, shares insights on frontline and relapsed treatments for DLBCL and follicular lymphoma. They explore the potential of bispecific antibodies, comparing their effectiveness, patient suitability, and safety in various scenarios. Their conversation reveals the evolving strategies and personalized approaches in lymphoma treatment.
AI Snips
Chapters
Transcript
Episode notes
Referral Gaps Limit CAR-T Use
- Many eligible patients never get CAR-T due to referral gaps, travel burden, caregiver needs, and perception of toxicity.
- Community access and shared decision-making are key to improving referral rates.
Mitigate Neurotoxicity Early
- Use steroids and early interventions to prevent severe ICANS and reduce length of stay when appropriate.
- Focus acute monitoring in the first several weeks; chronic CAR-T issues appear later.
Caregivers Often First To Spot ICANS
- ICANS often presents as an acute amnestic encephalopathy noticed first by caregivers rather than patients.
- Early CRS control reduces ICANS risk and prevents prolonged hospitalizations and rehabilitation needs.